* Abcellera Biologics Inc ABCL.OQ reported a quarterly
adjusted
loss of 14 cents per share for the quarter ended in March. The
mean expectation of seven analysts for the quarter was for a
loss of 14 cents per share.
* Revenue fell 96.1% to $12.19 million from a year ago;
analysts
expected $12.11 million.
* Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 14 cents.
* The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
* Abcellera Biologics Inc shares had fallen by 12.6% this
quarter and lost 34.9% so far this year.
* The company reported a quarterly loss of $40.11 million.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $29.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data May
4 at 09:41 p.m. UTC. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2023 -0.14 -0.14 Met
Dec. 31 2022 -0.01 -0.10 Missed
Sep. 30 2022 0.05 0.08 Beat
Jun. 30 2022 -0.02 -0.02 Met